Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 3/20 | 0.45 |
| ▸ | CDK2 | P24941 | 3/20 | 0.45 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.45 |
| ▸ | MAP2 | P11137 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 8/20 | 0.40 |
| ▸ | CCNC | P24863 | 7/20 | 0.40 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | F7 | P08709 | 1/20 | 0.38 |
| ▸ | F3 | P13726 | 1/20 | 0.38 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.38 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3985165 | 0.86 | MAP2 (0.46) | CCNA2CDK2CCNA1MAP2CDK8 | |
| SCHEMBL4716590 | 0.84 | DHODH (0.38) | MAP2KDM4ETDP1CSNK2A2CSNK2B | |
| SCHEMBL16516965 | 0.79 | ALDH1A1 (0.44) | CDK8CCNCKDM4EHTTMAP2K1 | |
| SCHEMBL12468204 | 0.78 | ELANE (0.37) | PIM1CLK2DYRK1ACSNK2A2CSNK2B | |
| SCHEMBL6649449 | 0.77 | CYP1A2 (0.47) | CCNA2CDK2CCNA1MAP2KDM4E | |
| SCHEMBL22623467 | 0.76 | MAPT (0.40) | KDM4ETDP1HTTABL1RPS6KA3 | |
| SCHEMBL18587754 | 0.75 | KDM5A (0.45) | KDM4EAURKAMEN1ALDH1A1MAPT | |
| SCHEMBL22623465 | 0.72 | KMT2A (0.43) | HTTMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL5267580 | 0.72 | AXL (0.37) | CDK2CDK8KDM4EHTTCHEK1 | |
| SCHEMBL5263268 | 0.71 | HTT (0.41) | HTTMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3143021-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | Pfizer Inc (US) | 2017-03-22 | — | — | EP | claimed |
| WO-2015173683-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | PFIZER INC. (US) | 2015-11-19 | — | — | WO | claimed |
| US-20260085077-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-03-26 | — | — | US | disclosed |
| US-20250320213-A1 | Nitrogen-Containing Heterocyclic Compounds | PFIZER INC. (US) | 2025-10-16 | — | — | US | disclosed |
| US-12281101-B2 | Bicyclic lactams and methods of use thereof | GENENTECH, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20240279240-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-08-22 | — | — | US | disclosed |
| US-20240209001-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | Chiesi Farmaceutici S.p. A. (IT) | 2024-06-27 | — | — | US | disclosed |
| US-11760733-B2 | Small molecule regulators of mitochondrial fusion and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220348559-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-11-03 | — | — | US | disclosed |
| US-20200281899-A1 | SMALL MOLECULE REGULATORS OF MITOCHONDRIAL FUSION AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY | 2020-09-10 | — | — | US | disclosed |
| EP-3704119-A1 | NOVEL, HIGHLY ACTIVE PYRAZOLO-PIPERIDINE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AiCuris GmbH & Co. KG (DE) | 2020-09-09 | — | — | EP | disclosed |
| EP-3036230-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2016-06-29 | — | — | EP | disclosed |
| WO-2016038045-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND THEIR USE IN THERAPY | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2016-03-17 | — | — | WO | disclosed |
| US-20150329542-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | PFIZER INC. | 2015-11-19 | — | — | US | disclosed |
| WO-2015173683-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | PFIZER INC. (US) | 2015-11-19 | — | — | WO | disclosed |
| WO-2015025025-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-26 | — | — | WO | disclosed |
| EP-2661433-A1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | Novartis AG (CH) | 2013-11-13 | — | — | EP | disclosed |
| WO-2012093101-A1 | INDOLE COMPOUNDS OR ANALOGUES THEREOF USEFUL FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | NOVARTIS AG (CH) | 2012-07-12 | — | — | WO | disclosed |
| EP-1689752-A1 | PYRAZOLOPYRIMIDINES | Pfizer Limited (GB) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005049617-A1 | PYRAZOLOPYRIMIDINES | PFIZER LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348559-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | LSS, LPXN, CYP1B1 | CCNA2 831/4885CDK2 1641/4885CCNA1 89/4885 |
| US-11760733-B2 | Small molecule regulators of mitochondrial fusion and methods of use thereof | MFN2, FIS1, RHOT2 | CCNA2 4721/4885CDK2 3603/4885CCNA1 4785/4885 |
| US-12281101-B2 | Bicyclic lactams and methods of use thereof | LSS, LPXN, CYP1B1 | CCNA2 831/4885CDK2 1641/4885CCNA1 89/4885 |
| US-20200281899-A1 | SMALL MOLECULE REGULATORS OF MITOCHONDRIAL FUSION AND METHODS OF USE THEREOF | MFN2, FIS1, RHOT2 | CCNA2 4721/4885CDK2 3603/4885CCNA1 4785/4885 |
| US-20260085077-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | TYK2, JAK1, JAK3 | CCNA2 2825/4885CDK2 405/4885CCNA1 1658/4885 |
| US-20250320213-A1 | Nitrogen-Containing Heterocyclic Compounds | HRH4, HNMT, NNT | CCNA2 2211/4885CDK2 2584/4885CCNA1 2532/4885 |
| US-20150329542-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | HRH2, HRH4, HRH1 | CCNA2 575/4885CDK2 823/4885CCNA1 724/4885 |
| US-20240279240-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | TYK2, JAK3, JAK1 | CCNA2 2175/4885CDK2 225/4885CCNA1 1673/4885 |
| US-20240209001-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | TYK2, JAK3, JAK1 | CCNA2 2172/4885CDK2 222/4885CCNA1 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.